Literature DB >> 31432385

Single- and dual-site ventricular pacing entirely through the coronary sinus for patients with prior tricuspid valve surgery.

Chin C Lee1, Khuyen Do1, Sati Patel1, Steven K Carlson1, Tomas Konecny1, Philip M Chang2, Rahul N Doshi3.   

Abstract

PURPOSE: Transvenous right ventricular pacing has traditionally been avoided after surgical tricuspid valve repair or replacement because of possible valvular dysfunction. Epicardial pacing has been used but it requires surgical thoracotomy and has higher lead failure rates when compared to transvenous pacing. We evaluated the lead stability and clinical outcomes in patients with isolated coronary sinus (CS) lead due to relative contraindication to transvenous pacing from prior tricuspid valve (TV) surgery.
METHODS: We retrospectively examined a single-center cohort of 34 patients with TV disease and/or surgery who underwent permanent pacemaker implantation with a left ventricular CS lead as the only ventricular pacing lead (to avoid crossing the TV). The clinical outcome, echocardiographic data, and pacing thresholds were evaluated at follow-up.
RESULTS: We implanted 19 patients with a single-CS lead and 15 patients with dual-CS leads. The average left ventricular ejection fraction was 56 ± 13% prior to lead implantation and remained stable at 2-year follow-up. The tricuspid regurgitation remained mild at follow-up. The average lead pacing threshold was 1.2 ± 0.6 V × ms at implant and 1.1 ± 0.4 V × ms at 2-year follow-up (P = 0.39). For patients with dual-CS leads, the pacing threshold was 1.2 ± 0.7 V × ms at implant and 1.1 ± 0.5 V × ms at 2-year follow-up (P = 0.52).
CONCLUSIONS: The use of ventricular pacing entirely through the CS is an effective and minimally invasive method that provides stable pacing for patients with prior TV surgery in whom transvenous lead placement either is not possible or is relatively contraindicated.

Entities:  

Keywords:  Cardiac resynchronization therapy; Left ventricular venous lead; Tricuspid valve repair; Tricuspid valve replacement; Tricuspid valve surgery

Mesh:

Year:  2019        PMID: 31432385     DOI: 10.1007/s10840-019-00599-8

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  32 in total

1.  Transvenous pacemaker leads do not worsen tricuspid regurgitation: a prospective echocardiographic study.

Authors:  D W Leibowitz; S Rosenheck; A Pollak; M Geist; D Gilon
Journal:  Cardiology       Date:  2000       Impact factor: 1.869

2.  Tricuspid valve repair: durability and risk factors for failure.

Authors:  Patrick M McCarthy; Sunil K Bhudia; Jeevanantham Rajeswaran; Katherine J Hoercher; Bruce W Lytle; Delos M Cosgrove; Eugene H Blackstone
Journal:  J Thorac Cardiovasc Surg       Date:  2004-03       Impact factor: 5.209

3.  Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up.

Authors:  Claudia Ypenburg; Rutger J van Bommel; C Jan Willem Borleffs; Gabe B Bleeker; Eric Boersma; Martin J Schalij; Jeroen J Bax
Journal:  J Am Coll Cardiol       Date:  2009-02-10       Impact factor: 24.094

4.  Influence of left ventricular lead location on outcomes in the COMPANION study.

Authors:  Leslie A Saxon; Brian Olshansky; Kent Volosin; Jonathan S Steinberg; Byron K Lee; Gery Tomassoni; Thomas Guarnieri; Anupama Rao; Patrick Yong; Elizabeth Galle; Jill Leigh; Fred Ecklund; Michael R Bristow
Journal:  J Cardiovasc Electrophysiol       Date:  2009-02-27

5.  Comparison of 1-year effects of left ventricular and biventricular pacing in patients with heart failure who have ventricular arrhythmias and left bundle-branch block: the Bi vs Left Ventricular Pacing: an International Pilot Evaluation on Heart Failure Patients with Ventricular Arrhythmias (BELIEVE) multicenter prospective randomized pilot study.

Authors:  Maurizio Gasparini; Mario Bocchiardo; Maurizio Lunati; Pier Antonio Ravazzi; Massimo Santini; Marco Zardini; Silvia Signorelli; Micaela Passardi; Catherine Klersy
Journal:  Am Heart J       Date:  2006-07       Impact factor: 4.749

6.  Severe symptomatic tricuspid valve regurgitation due to permanent pacemaker or implantable cardioverter-defibrillator leads.

Authors:  Grace Lin; Rick A Nishimura; Heidi M Connolly; Joseph A Dearani; Thoralf M Sundt; David L Hayes
Journal:  J Am Coll Cardiol       Date:  2005-05-17       Impact factor: 24.094

7.  Epicardial pacing: a single-centre study on 321 leads in 138 patients.

Authors:  Bavo Ector; Rik Willems; Hein Heidbüchel; Marc Gewillig; Luc Mertens; Bart Meyns; Willem Daenen; Hugo Ector
Journal:  Acta Cardiol       Date:  2006-06       Impact factor: 1.718

8.  Reduced ventricular volumes and improved systolic function with cardiac resynchronization therapy: a randomized trial comparing simultaneous biventricular pacing, sequential biventricular pacing, and left ventricular pacing.

Authors:  Rajni K Rao; Uday N Kumar; Jill Schafer; Esperanza Viloria; David De Lurgio; Elyse Foster
Journal:  Circulation       Date:  2007-04-09       Impact factor: 29.690

9.  The effect of transvenous pacemaker and implantable cardioverter defibrillator lead placement on tricuspid valve function: an observational study.

Authors:  Juyong B Kim; Daniel M Spevack; Paul A Tunick; John R Bullinga; Itzhak Kronzon; Larry A Chinitz; Harmony R Reynolds
Journal:  J Am Soc Echocardiogr       Date:  2007-07-02       Impact factor: 5.251

10.  Pacemaker therapy after tricuspid valve operations: implications on mortality, morbidity, and quality of life.

Authors:  Janne J Jokinen; Anu K Turpeinen; Otto Pitkänen; Mikko J Hippeläinen; Juha E K Hartikainen
Journal:  Ann Thorac Surg       Date:  2009-06       Impact factor: 4.330

View more
  1 in total

1.  Temporary coronary sinus pacing to improve ventricular dyssynchrony with cardiogenic shock: A case report.

Authors:  Teressa Reanne Ju; Hsin Tseng; Hsin-Ti Lin; Alexander Lee Wang; Chi Chan Lee; Yi-Ching Lai
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.